Elinzanetant (developmental code names BAY-3427080 GSK-1144814, NT-814) is an orally active small-molecule neurokinin/tachykinin NK1 receptor and NK3 receptor antagonist which is under development by Bayer, GlaxoSmithKline, and NeRRe Therapeutics for the treatment of hot flashes and "sex hormone disorders".

[1][2] It has been found to relieve hot flashes in postmenopausal women and to dose-dependently suppress luteinizing hormone, estradiol, and progesterone levels in premenopausal women.

[2][3] As of August 2021, elinzanetant is in phase 2 clinical trials for hot flashes and "sex hormone disorders".

[1] It was also under development for the treatment of schizophrenia and opioid-related disorders, but development was discontinued for these uses.

This drug article relating to the nervous system is a stub.